Greenwich LifeSciences (NASDAQ:GLSI) Earns “Buy” Rating from HC Wainwright

Greenwich LifeSciences (NASDAQ:GLSIGet Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a note issued to investors on Wednesday, Benzinga reports. They presently have a $36.00 price target on the stock. HC Wainwright’s price objective would suggest a potential upside of 175.23% from the stock’s current price. HC Wainwright also issued estimates for Greenwich LifeSciences’ Q1 2025 earnings at ($0.17) EPS, Q2 2025 earnings at ($0.17) EPS, Q3 2025 earnings at ($0.17) EPS, Q4 2025 earnings at ($0.17) EPS and FY2025 earnings at ($0.70) EPS.

Greenwich LifeSciences Stock Down 3.1 %

Shares of NASDAQ GLSI opened at $13.08 on Wednesday. The firm’s 50-day simple moving average is $15.37 and its 200 day simple moving average is $12.52. The company has a market cap of $168.47 million, a price-to-earnings ratio of -18.17 and a beta of 1.55. Greenwich LifeSciences has a 12-month low of $7.58 and a 12-month high of $21.44.

Greenwich LifeSciences (NASDAQ:GLSIGet Free Report) last issued its quarterly earnings results on Monday, April 15th. The company reported ($0.21) earnings per share (EPS) for the quarter. On average, equities analysts expect that Greenwich LifeSciences will post -0.76 earnings per share for the current year.

Insider Buying and Selling at Greenwich LifeSciences

In other Greenwich LifeSciences news, CEO Snehal Patel bought 2,500 shares of the business’s stock in a transaction on Friday, March 22nd. The shares were bought at an average cost of $19.98 per share, for a total transaction of $49,950.00. Following the transaction, the chief executive officer now owns 5,347,777 shares in the company, valued at approximately $106,848,584.46. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In the last three months, insiders have acquired 11,100 shares of company stock worth $187,133. Company insiders own 52.86% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Greenwich LifeSciences stock. Vanguard Group Inc. increased its position in shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSIFree Report) by 0.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 223,102 shares of the company’s stock after acquiring an additional 1,420 shares during the quarter. Vanguard Group Inc. owned about 1.73% of Greenwich LifeSciences worth $4,449,000 as of its most recent SEC filing. 4.16% of the stock is owned by hedge funds and other institutional investors.

Greenwich LifeSciences Company Profile

(Get Free Report)

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.

Read More

Receive News & Ratings for Greenwich LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenwich LifeSciences and related companies with's FREE daily email newsletter.